KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Common Equity (2016 - 2025)

Historic Common Equity for Moderna (MRNA) over the last 10 years, with Q3 2025 value amounting to $9.3 billion.

  • Moderna's Common Equity fell 2177.41% to $9.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 billion, marking a year-over-year decrease of 2177.41%. This contributed to the annual value of $10.9 billion for FY2024, which is 2131.51% down from last year.
  • Per Moderna's latest filing, its Common Equity stood at $9.3 billion for Q3 2025, which was down 2177.41% from $9.4 billion recorded in Q2 2025.
  • In the past 5 years, Moderna's Common Equity registered a high of $19.1 billion during Q4 2022, and its lowest value of $3.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Common Equity was $12.8 billion (2024), whereas its average is $13.0 billion.
  • In the last 5 years, Moderna's Common Equity skyrocketed by 45232.33% in 2021 and then plummeted by 3205.22% in 2024.
  • Over the past 5 years, Moderna's Common Equity (Quarter) stood at $14.1 billion in 2021, then surged by 35.19% to $19.1 billion in 2022, then decreased by 27.55% to $13.9 billion in 2023, then fell by 21.32% to $10.9 billion in 2024, then decreased by 14.41% to $9.3 billion in 2025.
  • Its Common Equity was $9.3 billion in Q3 2025, compared to $9.4 billion in Q2 2025 and $10.1 billion in Q1 2025.